This site is intended for U.S. healthcare professionals.
Studies in support of biosimilarity in healthy volunteers
PD=pharmacodynamic; PK=pharmacokinetic.
Studies in support of biosimilarity in healthy volunteers
Eligible,¶ commercially insured patients# may pay as little as $0 per NYVEPRIA treatment.** See full Terms and Conditions below.
*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.1
†NYVEPRIA does not have a designation of interchangeability with Neulasta.
‡WAC is a manufacturer’s undiscounted or list price to wholesalers/direct purchasers and, therefore, is not inclusive of discounts to payers, providers, distributors, and other purchasing organizations. Data as of May 2022.
§Percentage of commercial lives where NYVEPRIA is covered at parity or at an advantage to Neulasta.
‖Medical policy data are current as of April 2022. Please verify individual patient benefits to confirm coverage.
¶Terms and Conditions: By using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions below:
#For patients to be eligible for the Injectables Co-Pay Program for NYVEPRIA, they must have commercial insurance that covers NYVEPRIA and they cannot be enrolled in a state or federally funded insurance program. Whether a co-pay expense is eligible for the Injectables Co-Pay Program for NYVEPRIA benefit will be determined at the time the benefit is paid. Co-pay expenses must be in connection with a separately paid claim for NYVEPRIA administered in the outpatient setting.
**The Injectables Co-Pay Program for NYVEPRIA will pay the co-pay for NYVEPRIA up to the annual assistance limit of $10,000 per calendar year per patient.
††The Injectables Co-Pay Program for NYVEPRIA provides assistance for eligible, commercially insured patients prescribed NYVEPRIA for co-pays or coinsurance incurred for NYVEPRIA up to $10,000 per calendar year. It does not cover or provide support for supplies, services, procedures, or any other physician-related services associated with NYVEPRIA treatment.
References:
NYVEPRIA is a trademark of Pfizer Inc.
Neulasta® (pegfilgrastim) is a registered trademark of Amgen Inc.
NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use
NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.
NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Please see full Prescribing Information, Patient Information, and Instructions for Use for NYVEPRIA.
Please see full Prescribing Information.
OK. We'll need you to sign in before we can determine if you are aligned with a sales representative.
If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.
Would you like to sign in now?